TY - JOUR
T1 - Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor
AU - Tamakoshi, Koji
AU - Kikkawa, Fumitaka
AU - Shibata, Kiyosumi
AU - Tomoda, Kiyoshi
AU - Obata, Naoko H.
AU - Wakahara, Fumiyo
AU - Tokuhashi, Yahito
AU - Ishikawa, Hisatake
AU - Kawai, Michiyasu
AU - Tomoda, Yutaka
N1 - Funding Information:
1This work was supported in part by a grant to Yutaka Tomoda (02404067) from the Ministry of Education. 2To whom correspondence and reprint requests should be addressed. Fax: (Japan) 52 731 6136.
PY - 1996/7
Y1 - 1996/7
N2 - Five tumor markers were analyzed clinically in 101 patients with borderline ovarian tumors who were treated by the Tokai Ovarian Tumor Study Group, an association comprising Nagoya University and its affiliated hospital, between January 1986 and December 1994. The positive rate of CA125 was 68.2% in serous tumor and 51.9% in mucinous tumor. The positive rate of CA19-9 was 51.5% in serous tumor and 44.7% in mucinous tumor. The positive rates and mean serum levels of CA125 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. The mean serum levels of CA19-9 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. CA125 and CA19-9 were useful for screening of borderline ovarian tumors. The positive rates of CEA and TPA in mutinous tumor were 32.5 and 27.3%, respectively, although none of the patients with serous tumor were positive in CEA and TPA. The positive rates and mean serum levels of CEA in mucinous tumor by stage had rising tendencies with an increase in each stage. The positive rate of CA72-4 was significantly lower than that of CA125 (P < 0.05).
AB - Five tumor markers were analyzed clinically in 101 patients with borderline ovarian tumors who were treated by the Tokai Ovarian Tumor Study Group, an association comprising Nagoya University and its affiliated hospital, between January 1986 and December 1994. The positive rate of CA125 was 68.2% in serous tumor and 51.9% in mucinous tumor. The positive rate of CA19-9 was 51.5% in serous tumor and 44.7% in mucinous tumor. The positive rates and mean serum levels of CA125 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. The mean serum levels of CA19-9 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. CA125 and CA19-9 were useful for screening of borderline ovarian tumors. The positive rates of CEA and TPA in mutinous tumor were 32.5 and 27.3%, respectively, although none of the patients with serous tumor were positive in CEA and TPA. The positive rates and mean serum levels of CEA in mucinous tumor by stage had rising tendencies with an increase in each stage. The positive rate of CA72-4 was significantly lower than that of CA125 (P < 0.05).
UR - https://www.scopus.com/pages/publications/0030200820
UR - https://www.scopus.com/pages/publications/0030200820#tab=citedBy
U2 - 10.1006/gyno.1996.0191
DO - 10.1006/gyno.1996.0191
M3 - Article
C2 - 8690294
AN - SCOPUS:0030200820
SN - 0090-8258
VL - 62
SP - 67
EP - 72
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -